These results suggest that high-risk MDS-MSC may inhibit effective immune responses against the dysplastic clone by inducing CD4+CD25+Foxp3+Tregs, thereby facilitating disease progression. This evidence concerns the gene FOXP3 and myelodysplastic syndrome.